Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(3.50)
# 923
Out of 5,044 analysts
57
Total ratings
43.14%
Success rate
8.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Reiterates: Overweight | n/a | $52.42 | - | 2 | Sep 3, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $18.38 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $28.95 | +124.53% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $13.43 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $29.81 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $2.39 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $15.18 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $0.96 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $4.92 | +103.46% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $429.18 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.82 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $54.00 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.13 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $34.55 | -30.54% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.69 | +16,628.62% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $1.35 | +937.04% | 1 | Mar 3, 2021 |
Metsera
Sep 3, 2025
Reiterates: Overweight
Price Target: n/a
Current: $52.42
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $18.38
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $28.95
Upside: +124.53%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.43
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $29.81
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.39
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $15.18
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.92
Upside: +103.46%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $429.18
Upside: -
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.82
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $54.00
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $30.13
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $34.55
Upside: -30.54%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.69
Upside: +16,628.62%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $1.35
Upside: +937.04%